Epaminurad
- Generic Name
- Epaminurad
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06435442
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT05198778
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju, Korea, Republic of
π°π·Ajou University Hospital, Suwon, Korea, Republic of
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 76
- Registration Number
- NCT02557126
- Locations
- π°π·
JW Pharmaceutical, Seoul, Seocho-dong, Korea, Republic of
Phase 1 Study(Additional) of URC102 in Healthy Subjects
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 21
- Registration Number
- NCT02524678
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Phase 1 Study of URC102 in Healthy Subjects
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 81
- Registration Number
- NCT01953497
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath